BeyondSpring is trading at $0.59, up 18.98%, with no clear company-specific catalyst identified for the October 22 rise.

  • BeyondSpring was reported up 12.9% to $0.56 in pre-market trading; the report also noted the XBI biotech ETF was up 3.64%, but did not establish a link.
  • The Nasdaq market-value compliance notice dates to September 29, not October 22, and does not explain the gain.
  • Major market indices were down in the supplied context, offering no same-direction broad-market explanation.